Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Frontline Ribociclib-Related Quality of Life Favorable to Abemaciclib in HR+/HER2- Advanced Breast Cancer

      July 15, 2022
      By Lindsay Fischer
      Article

      Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.

      Hope S. Rugo, MD, FACP

      Hope S. Rugo, MD, FACP

      Frontline treatment with ribociclib (Kisqali) and aromatase inhibition for hormone receptor–positive, HER2-negative advanced breast cancer was associated with better symptom-related quality of life (QOL) scores vs the combination of abemaciclib (Verzenio) and an aromatase inhibitor in the same setting. Investigators conducted a matched-adjusted indirect comparison (MAIC) using published data from individual patients treated in the MONALEESA-2 (NCT01958021) and MONARCH-3 trials (NCT02246621). The MAIC analysis was presented at the 2022 ASCO Annual Meeting.

      Ribociclib was favorable over abemaciclib in reducing diarrhea, fatigue, appetite loss, and arm symptoms (such as pain or swelling in the shoulder or arm and difficulty raising the arm). Results of a prior survey identified these symptoms as having a moderate to severe effect on QOL among patients treated with CDK4/6 inhibitors.

      “Ribociclib plus endocrine therapy demonstrated statistically significant improvement in overall survival [OS] across the MONALEESA [trials],” Hope Rugo, MD, FASCO, of the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, explained in a presentation of the findings. Rugo added that ribociclib, when added to an aromatase inhibitor, demonstrated the longest median OS to date of any intention-to-treat population.

      CDK4/6 inhibitors plus endocrine therapy is the standard of care in the frontline treatment of patients with hormone receptor–positive, HER2-negative advanced breast cancer; however, these agents are known to have different safety profiles because of their different inhibition targets. Furthermore, because mild adverse events (AEs) can have a significant effect on a patient’s experience, patient-reported outcomes (PROs) can be useful in helping inform treatment decision-making.

      In the absence of a direct head-to-head study, investigators decided to conduct a MAIC analysis of the PRO data between the 2 studies. The PALOMA-2 trial, which evaluated palbociclib (Ibrance) plus an aromatase inhibitor, could not be included because the PRO data assessed different markers than MONALEESA-2 and MONARCH-3.

      MONALEESA-2 evaluated patients who had been randomized 1:1 to receiver either frontline ribociclib plus letrozole or placebo plus letrozole; MONARCH-3 compared the outcomes of patients who were assigned 2:1 to receive either abemaciclib plus nonsteroidal aromatase inhibition or the nonsteroidal aromatase inhibitor as monotherapy. Both trials enrolled patients who had received no systematic treatment for their advanced breast cancer. In addition, MONALEESA-2 included patients with measurable disease as defined by RECIST 1.1 or at least 1 predominately lytic bone lesion, and who had a treatment-free interval greater than 12 months following prior neoadjuvant or nonsteroidal aromatase inhibitor therapy. MONARCH-3 required patients to have measurable disease or nonmeasurable bone-only disease, including blastic, lytic, or mixed, as defined by RECIST 1.1, to have adequate organ function, and to have had a treatment-free interval greater than 12 months following prior neoadjuvant endocrine therapy.

      Exclusion criteria included prior treatment with CDK/4 inhibitors, presence of active cardiac disease or dysfunction, and presence of inflammatory breast cancer in MONALEESA-2; prior treatment with everolimus or a CDK4/6 inhibitor, the presence of visceral crisis, lymphangitic spread, leptomeningeal carcinomatosis, or inflammatory breast cancer, and evidence or history of central nervous metastases all represented exclusion criteria in MONARCH-3.

      After matching and balancing the inclusion and exclusion criteria, investigators had a sample of 354 and 493 evaluable patients from the MONALEESA-2 and MONARCH-3 trials, respectively.

      Across the functional domains included in the European Organization for Research and Treatment of Cancer QLQ-C30 and BR23 questionnaire, no significant differences were detected. However, time to sustained deterioration (TTSD) numerically favored the ribociclib in terms of emotional (HR, 0.77; 95% CI, 0.45-1.32), role (HR, 0.66; 95% CI, 0.41-1.06), and social functioning (HR, 0.80; 95% CI, 0.49-1.31) in the QLQ-C30 questionnaire. Body image (HR, 0.82; 95% CI, 0.47-1.44), future perspective (HR, 0.61; 95% CI, 0.34-1.08), and sexual functioning scores (HR, 0.50; 95% CI, 0.24-1.01) all favored ribociclib in the BR23 questionnaire.

      Furthermore, the TTSD analysis revealed that ribociclib scored better across 4 key symptom scales; the agent was linked to more manageable appetite loss (HR, 0.46; 95% CI, 0.27-0.81), diarrhea (HR, 0.42; 95% CI, 0.23-0.79), fatigue (HR, 0.63; 95% CI, 0.41-0.96), and arm symptoms (HR, 0.50; 95% CI, 0.24-1.01).

      Abemaciclib did not perform better than ribociclib across any of these domains; however, nausea/vomiting (HR, 1.09; 95% CI, 0.63-1.86) and breast symptoms (HR, 1.26; 95% CI, 0.62-2.55) favored abemaciclib. Additionally, financial toxicity outcomes were better with abemaciclib (HR, 1.13; 95% CI, 0.60-2.14).

      Study authors noted that the analysis only used published patient characteristics form the 2 studies, and unreported factors could potentially confound these data.

      Reference

      Rugo HS, O’Shuaghnessey J, Jhaveri KL, et al. Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). J Clin Oncol. 2022;40(suppl 16):1015. doi:10.1200/JCO.2022.40.16_suppl.1015

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
      Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      Photo of a man wearing glasses and a suit in front of a blue background
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      Photo of Hope Rugo, MD
      Image of a woman with blond hair in front of a dark blue background
      Photo of a woman smiling in front of a dark blue background
      Image of a woman with blonde hair wearing a black shirt in front of a blue background
      Image of a woman with light brown hair wearing glasses with a blue background
      Related Content

      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Graphic of a person with a breast tumor

      Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

      Bridget Hoyt
      July 16th 2025
      Article

      Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.


      Graphic of a breast with a tumor

      Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

      Jax DiEugenio
      July 14th 2025
      Article

      Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

      Related Content

      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Graphic of a person with a breast tumor

      Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

      Bridget Hoyt
      July 16th 2025
      Article

      Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.


      Graphic of a breast with a tumor

      Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

      Jax DiEugenio
      July 14th 2025
      Article

      Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

      Latest Conference Coverage

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers

      Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.